Hospira Receives FDA Approval of Topotecan Injection

Hospira, Inc. HSP today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States. The medication is a generic version of Hycamtin, which had 2010 U.S. sales of more than $140 million. Hospira's topotecan is indicated for treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. The solution formulation of topotecan, with a concentration of 4 mg/4 ml, is designed to improve caregiver convenience and safety, and Hospira expects to launch the product by the end of February.